Meda AB: FDA Finds the NDA for Dymista Sufficiently Complete

GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: MEDA AB: (STO:MEDAA) The New Drug Application (NDA) for Dymista has been accepted by the U.S. Food and Drug Administration (FDA) as sufficiently complete to permit a substantive review.